| Current Price | $41.50 | Mkt Cap | $1.7B |
|---|---|---|---|
| Open | $42.00 | P/E Ratio | 0.00 |
| Prev. Close | $41.50 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $39.70 - $42.77 | Volume | 1,684,264 |
| 52-Wk Range | $13.84 - $100.00 | Avg. Daily Vol. | 4,710,182 |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
| Current Price | $41.50 | Mkt Cap | $1.7B |
|---|---|---|---|
| Open | $42.00 | P/E Ratio | 0.00 |
| Prev. Close | $41.50 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $39.70 - $42.77 | Volume | 1,684,264 |
| 52-Wk Range | $13.84 - $100.00 | Avg. Daily Vol. | 4,710,182 |
The best Bull and Bear pitches based on recency and number of recommendations.
The potential for growth in Alzheimer's drugs is huge as our population ages. Cassava has a diagnostic blood test for Alzheimer's in the works and a therapy to treat the disease also in trials.
My 5 year old son just asked “what if we put a slice of turkey in the DVD player and it played a movie about the turkey’s whole life” and none of the parenting books I’ve read have prepared me for this question.
Read the most recent pitches from players about SAVA.
Recs
TMFjimhalley
(< 20)
Submitted: 7/12/2021 6:46:55 PM :
Start Price:
$100.15
NASDAQ:SAVA Score:
-42.59
The potential for growth in Alzheimer's drugs is huge as our population ages. Cassava has a diagnostic blood test for Alzheimer's in the works and a therapy to treat the disease also in trials.
Recs
kfox
(< 20)
Submitted: 2/2/2021 4:28:30 PM :
Start Price:
$33.39
NASDAQ:SAVA Score:
+28.43
They just released information of a trial they did with their treatment for Alzheimer's Disease. The results of the trial were positive, patients had an improvement in cognition and behavior. the name of the treatment/drug is Simufilam.
Recs
capptten
(< 20)
Submitted: 11/30/2020 8:05:16 PM :
Start Price:
$7.66
NASDAQ:SAVA Score:
+441.50
This is a high risk high reward stock. The company has changed the name to Cassava Science. The have completed a stage 2 study and raised and additional 75 million to bring cash up to about 94 million. This will allow them to do a stage 3 study which they will be meeting the FDA in January. The stage 2 showed improved many improved biomarkers and there were some stories of caregivers noticing improvement in some patients behaviors. All of this information is readily available. The company decided to raise the money to complete more studies than sell the at a discounted price. If this study goes well most feel that this company would be bought out in excess of $100 per share. I encourage you to read and do your own DD.
Find the members with the highest scoring picks in SAVA.
medeaschild (75.01) Score: +5,300.15
The Score Leader is the player with the highest score across all their picks in SAVA.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| medeaschild | 75.01 | 12/26/2018 |
|
NS | $0.76 | +5,355.50% | +55.35% | +5,300.15 | 0 Comment | |
| SmallCapSurfer2 | 71.13 | 10/13/2016 |
|
3M | $5.32 | +680.08% | +72.78% | +607.29 | 0 Comment | |
| capptten | < 20 | 12/1/2020 |
|
3M | $7.66 | +441.78% | +0.28% | +441.50 | 1 Comment | |
| foolrrrrrrrrrr | 34.20 | 11/13/2008 |
|
1Y | $37.61 | +10.35% | +345.05% | +334.70 | 0 Comment | |
| jornoski | 28.85 | 9/21/2020 |
|
5Y | $9.45 | +339.15% | +12.55% | +326.60 | 0 Comment | |
| OklaBoston | 48.43 | 9/21/2020 |
|
3Y | $9.45 | +339.15% | +12.55% | +326.60 | 1 Comment | |
| Dennyf10 | 57.87 |
|
|
1Y | $35.72 | +16.17% | +310.84% | +294.68 | 0 Comment | |
| marcet | 74.20 | 3/2/2009 |
|
3W | $18.82 | +120.46% | +414.45% | +293.99 | 0 Comment | |
| hackerbobZ | < 20 | 3/23/2009 |
|
5Y | $17.65 | +135.09% | +370.42% | +235.33 | 0 Comment | |
| deemonfather42 | < 20 | 7/6/2009 |
|
3W | $22.42 | +85.09% | +311.88% | +226.79 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
